The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design

Inclusion Criteria 1. Healthy males and females, between 18 and 65 years of age. 2. Subject has Black or dark brown terminal hairs in the areas to be treated. 3. Terminal hair density requirement of greater than 15 hairs within the hair count site (3x3 cm area) as determined by manual hair count performed by the study investigator. 4. Willing to sign informed consent. 5. Willing to follow the treatment schedule and post treatment follow-up. 6. Willingness to have photographs of the treated area taken that may be used for marketing and educational presentation and/or publications 7. Willingness to avoid excessive sun exposure two weeks prior to treatments Exclusion Criteria Skin and Hair 1. Subjects with white, red, light brown and/ or blonde hairs in the areas to be treated. 2. A history of keloidal scarring (hypertrophic scars or keloids). 3. Active dermatologic lesion or infection in the treatment site. 4. Subject has permanent tattoos or makeup in the treatment area. 5. Recently tanned in the area to be treated and/or unable or unlikely to refrain from tanning during the study. 6. Subject has disease related to photosensitivity, such as porphyria, polymorphic light eruption, solar urticaria, lupus, etc 7. Subject has a history of herpes outbreak in the area of treatment, unless receiving preventative treatment from physician Other Medical Conditions 8. Pregnant, planning to become pregnant, hormone fluctuations and/or breast feeding during the experiment. 9. Subjects with Diabetes (Type I or II) or other systemic or metabolic condition 10. Subject has an active electrical implant anywhere in the body, such as a pacemaker, an internal defibrillator, insulin pump, incontinence device, etc. 11. Subject suffers from epilepsy. 12. Subject has active cancer, or has a history of skin cancer or any other cancer in the area to be treated, including presence of malignant or pre-malignant pigmented lesions. 13. Subject received radiation therapy or chemotherapy treatments with the past 3 months. 14. Subject has known anticoagulative or thromboembolic condition or is on any form of anticoagulation treatment. 15. Subject has a history of immunosuppressant/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications. 16. Subject has any other condition which in the physician's opinion would make it unsafe for the subject to be treated. Medication/treatments 17. Subject had rotating type tweezer epilator treatment, or waxing within the last 3 weeks 18. Subject had electrolysis treatment within the last 6 months over the treatment area. 19. Subject had any type of professional intense pulsed light (IPL), laser or RF hair removal in the treatment site within the last 6 months. 20. Subject is taking medication known to induce photosensitivity, including non-steroidal anti-inflammatory agents, tetracyclines, phenothiazines, thiazide diuretics, sulfonylureas, sulfonamides, Dacarbazine(DTIC), fluorouracil, vinblastine, and griseofulvin within 4 weeks of therapy. 21. Subject has been taking Accutane® within 6 months of therapy. 22. Subject has been on steroid regimen during the last three months. 23. Subject is on Gold therapy (for arthritis treatment).